骨肉瘤CDKN2/P16基因外显因子2缺失率与病理分型、转移能力及性别的相关性

Osteosarcomaisacommontumorwhichoccupiesthefirstplaceinmalignantbonetumorwith44.8%.Itoftenoccursattheage10～20yearsoldwithyoungerage,highermalignancy,morerapidadvancing,earliermetastasismore,difficultfoundingandbadprog-nosisasitsmanifestation.Soithasanimportantsignificancetostudyongenesis,advancingandmetastasis.Thisresearchanalysisalternationofexon2whichwasoftenfounddeletionandmutationbyPCR-SSCPsilverstainingmethod.1Subjectsandmethods1.1Clinicdata25casesofosteosarcomawereinvestigatedinChang…

Relationship between exon deletion frequency of CDKN2/P16 and pathological type,metastasis,sex in osteosarcoma

Objective To study on the CDKN2/P16 gene in primary osteosarcoma.Method By using molecular biological methods that inclued genome DNA extraction from paraffined tissue and PCR SSCP analysis technique, we studied alternations of CDKN2/P16 gene in 25 primary osteosarcomas.Results (1)The deletions frequency in differentiation degree of osteosarcomas was① bone brood cell, 16.7% ;② cartilage brood cell,12.5% ;③ Fiber brood cell:20% ,(P >0.05).(2)The deletion frequency in male patients was 17.6% , female patients 12.5% ,(P >0.05).(3)In early metastatic osteosarcomas the deletion rate was 33.3% ,which was significantly higher than that of the control group with the rate of 10.5% (P< 0.05).(4)The deletion rate was 16% and the mutations were not found.Conclusion (1)The deletion rate was 16% and the mutations were not found.This suggests that the deletions of CDKN2/P16 gene were closely related to the genesis of primary osteosarcoma and that the main type of the alternation of CDKN2/P16 gene was deletion.(2)In early metastatic osteosaarcomas the deletion rate was 33.3% , which was significantly higher than that of the control group with the rate of 10.5% .This indicates to great extend that the deletions of CDKN2/P16 gene were closely related to the metastatic ability.(3)The deletions frequency had no significant relationship with differentiation degree of osteosarcomas, so was with the sex of the patient.